The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The emerging role of splicing factors in cancer
Open accessAbstract
Recent progress in global sequence and microarray data analysis has revealed the increasing complexity of the human transcriptome. Alternative splicing generates a huge diversity of transcript variants and disruption of splicing regulatory networks is emerging as an important contributor to various diseases, including cancer. Current efforts to establish the dynamic repertoire of transcripts that are generated in health and disease are showing that many cancer‐associated alternative‐splicing events occur in the absence of mutations in the affected genes. A growing body of evidence reveals changes in splicing‐factor expression that correlate with cancer development, progression and response to therapy. Here, we discuss how recent links between cancer and altered expression of proteins implicated in splicing regulation are bringing the splicing machinery to the fore as a potential target for anticancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Izquierdo, J. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800017200 · Cited by 156
Notch3 and the Notch3‐upregulated RNA‐binding protein HuD regulate Ikaros alternative splicing
Bellavia, D., Mecarozzi, M., Campese, A. F., Grazioli, P., Talora, C., Frati, L., Gulino, A., & Screpanti, I. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601626 · Cited by 80
Cited by
Cooper, T. A., Wan, L., & Dreyfuss, G. (2009) · Cell · doi:10.1016/j.cell.2009.02.011 · Cited by 1,159
Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged
David, C. J., & Manley, J. L. (2010) · Genes & Development · doi:10.1101/gad.1973010 · Cited by 814
RNA processing and its regulation: global insights into biological networks
Licatalosi, D. D., & Darnell, R. B. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2673 · Cited by 763
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes
Graubert, T. A., Shen, D., Ding, L., Okeyo-Owuor, T., Lunn, C. L., Shao, J., Krysiak, K., Harris, C. C., Koboldt, D. C., Larson, D. E., et al. (2012) · Nature Genetics · doi:10.1038/ng.1031 · Cited by 580
Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes
Sveen, A., Kilpinen, S., Ruusulehto, A., Lothe, R. A., & Skotheim, R. I. (2016) · Oncogene · doi:10.1038/onc.2015.318 · Cited by 470
Clower, C. V., Chatterjee, D., Wang, Z., Cantley, L. C., Vander Heiden, M. G., & Krainer, A. R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914845107 · Cited by 424
“In addition, other splicing repressors, such as hnRNPA1 and hnRNPA2, and activators, such as SF2/ ASF, have been implicated in oncogenic transformation (2, 3), and hence could potentially play a role in PK-M alternative splicing.”
BackgroundWard, A. J., & Cooper, T. A. (2010) · The Journal of Pathology · doi:10.1002/path.2649 · Cited by 414
Cancer-associated regulation of alternative splicing
Venables, J. P., Klinck, R., Koh, C., Gervais-Bird, J., Bramard, A., Inkel, L., Durand, M., Couture, S., Froehlich, U., Lapointe, E., et al. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1608 · Cited by 342
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)
Meggendorfer, M., Roller, A., Haferlach, T., Eder, C., Dicker, F., Grossmann, V., Kohlmann, A., Alpermann, T., Yoshida, K., Ogawa, S., et al. (2012) · Blood · doi:10.1182/blood-2012-01-404863 · Cited by 311
Misregulation of Pre-mRNA Alternative Splicing in Cancer
Zhang, J., & Manley, J. L. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0253 · Cited by 307
Tang, Y., Horikawa, I., Ajiro, M., Robles, A. I., Fujita, K., Mondal, A. M., Stauffer, J. K., Zheng, Z.-M., & Harris, C. C. (2013) · Oncogene · doi:10.1038/onc.2012.288 · Cited by 165
Activation of Src and transformation by an RPTPα splice mutant found in human tumours
Huang, J., Yao, L., Xu, R., Wu, H., Wang, M., White, B. S., Shalloway, D., & Zheng, X. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.212 · Cited by 27
Metadata
- Authors
- Grosso, A. R., Martins, S., & Carmo‐Fonseca, M.
- Venue
- EMBO reports
- Published
- 2008-10
- Volume
- 9
- Issue
- 11
- Pages
- 1087-1093
- ISSN
- 1469-221X (ISSN-L)
- 1469-3178
- OpenAlex
- W2101636442
- Cited by
- 179
- References
- 2
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.